Which alt-protein companies received investment?

This blog post has been written by the person who has mapped the alternative protein market in a clean and beautiful presentation

The alternative protein investment landscape has shifted dramatically, with funding declining 29% to $1.1 billion in 2024 after peaking in 2023.

Despite this contraction, precision fermentation and biomass fermentation captured over 50% of total funding, while geographic concentration favored North America and Europe. The sector shows clear signs of maturation with larger rounds going to companies with proven commercial traction and established distribution networks.

And if you need to understand this market in 30 minutes with the latest information, you can download our quick market pitch.

Which alternative protein companies raised the most funding in 2024 and 2025?

Meati led all alternative protein funding in 2024 with a $100 million Series C1 round from Grosvenor Food & AgTech, driven by their expansion to 10,000 retail outlets and proven consumer demand for mycelium-based whole-cut meats.

Perfect Day secured $90 million in Series E funding from existing backers, capitalizing on their market leadership position in precision-fermented dairy proteins and regulatory approvals in the US and Singapore. The company has established partnerships with major food manufacturers for ice cream and cheese applications.

European companies dominated the next tier of funding, with Formo raising $61 million in Series B funding led by FoodLabs and The Nature Conservancy for their koji-based cream cheese technology. Infinite Roots followed closely with $58 million from Dr. Hans Riegel Holding and the EIC Fund, focusing on mycelium-derived proteins for the European market where novel food regulations are more favorable.

Prolific Machines raised $55 million in Series B1 funding from The Ki Tua Fund (Fonterra's VC arm) and Breakthrough Energy Ventures, backing their photomolecular technology that uses light to control cellular metabolism in cultivated meat production. This approach promises significant cost reductions compared to traditional bioreactor methods.

The Q1 2025 leaders included Formo with an additional $36 million Series A, Vivici with $33.8 million for fermented fungal seafood proteins, and Liberation Labs with $31.5 million for precision-fermented dairy proteins, showing continued investor confidence in fermentation technologies.

Who are the major investors backing alternative protein companies and what's their investment strategy?

Grosvenor Food & AgTech emerged as the most active alternative protein investor in 2024, leading Meati's $100 million round while maintaining a portfolio focused on climate-tech ventures including Redwood Materials and other decarbonization technologies.

Breakthrough Energy Ventures, Bill Gates's fund, participated in Prolific Machines' round as part of their broader strategy targeting energy-efficient biotechnology companies like Antheia and Pivot Bio. Their focus centers on technologies that can achieve significant scale with improved unit economics.

European investors showed strong sector commitment, with FoodLabs and The Nature Conservancy co-leading Formo's round while building portfolios around sustainability and agricultural technology. The EIC Fund (European Innovation Council) backed multiple companies including Infinite Roots and Onego Bio, reflecting EU policy support for novel food technologies.

Corporate venture arms played crucial roles, particularly M Ventures (Merck KGaA's VC arm) which led Mosa Meat's funding and focuses on life sciences and precision fermentation investments. The Ki Tua Fund from Fonterra targeted Prolific Machines, aligning with their dairy industry expertise and interest in cellular agriculture applications.

Specialized biotech investors like Avidity Partners led Helaina's $45 million round, focusing specifically on precision fermentation and biotech startups with clear paths to commercial scale and regulatory approval.

If you want fresh and clear data on this market, you can download our latest market pitch deck here

What funding stages and amounts characterized the 2024-2025 investment landscape?

Series B and later-stage rounds dominated the largest investments, with companies like Meati (Series C1), Perfect Day (Series E), and Formo (Series B) raising the most substantial amounts, indicating investor preference for companies with proven commercial traction.

Which technologies and R&D breakthroughs are attracting the most investment?

Precision fermentation captured over 50% of total funding in 2024-Q1 2025, with investors betting on companies producing animal-identical proteins through engineered microorganisms, particularly for dairy applications where regulatory pathways are clearest.

Biomass and mycelium fermentation received record investments, led by Meati's $100 million round and Infinite Roots' $58 million funding, as investors recognize fungal-based whole proteins can achieve price parity with conventional meat faster than cellular agriculture approaches.

Photomolecular platforms like Prolific Machines attracted $55 million for their innovative use of light-mediated cell growth, which promises to reduce cultivated meat production costs by 90% compared to traditional bioreactor methods while increasing production speed.

Novel applications in infant nutrition drew significant attention, with Helaina raising $45 million for precision-fermented human lactoferrin, addressing the $70 billion infant formula market where functional proteins command premium pricing.

Looking for the latest market trends? We break them down in sharp, digestible presentations you can skim or share.

Which geographies are leading alternative protein investment and why?

North America captured approximately 60% of total alternative protein funding in 2024, driven by a robust venture capital ecosystem, corporate funding from companies like PepsiCo and Cargill, USDA grant programs, and the world's largest consumer market for alternative proteins.

Europe secured around 30% of global funding with nearly €470 million invested, representing 23% year-over-year growth led by precision fermentation (€120 million) and biomass fermentation (€119 million) investments, supported by EU Horizon Europe funding and EIC grants.

Germany emerged as Europe's leading hub with companies like Formo and Infinite Roots raising significant rounds, benefiting from strong government support for circular bioeconomy policies and proximity to major food manufacturers like Rewe Group that participated directly in funding rounds.

Asia-Pacific captured approximately 10% of funding despite growing government support in Singapore and Japan, with nascent VC interest but significant public R&D pilot projects indicating future growth potential as regulatory frameworks develop.

The geographic concentration reflects regulatory maturity, with the US and EU offering clearer paths to market approval through GRAS status and Novel Food regulations respectively, while Asian markets remain largely in pilot project phases.

Which established food and biotech giants are investing in alternative protein ventures?

CPG giants are taking direct equity positions and forming strategic partnerships, with Fonterra investing through The Ki Tua Fund in Prolific Machines, Rewe Group backing both Formo and Infinite Roots, and Upfield leading Heura's Series B round to expand plant-based meat offerings.

Biotech and pharmaceutical companies are targeting precision fermentation, with Merck KGaA's M Ventures leading Mosa Meat's funding and Tetra Pak investing in animal-free casein scale-up technologies that align with their packaging and processing equipment businesses.

Agricultural commodities companies like Cargill continue expanding their alternative protein portfolios through direct investments and pilot partnerships, particularly with Perfect Day for dairy protein applications that complement their existing ingredient supply chains.

Corporate venture arms from Mitsubishi, PepsiCo, and other multinationals are taking minority stakes while providing market access, manufacturing capabilities, and distribution networks that early-stage companies need for commercial scale-up.

Government and multilateral organizations provide non-dilutive funding through EU Horizon Europe programs, USDA loans (notably to Voyage Foods), and EIC Fund investments, reducing private investor risk while supporting R&D intensive technologies.

If you want to build or invest on this market, you can download our latest market pitch deck here

What are the business models and go-to-market strategies of top-funded companies?

B2B ingredient suppliers dominate the precision fermentation space, with Perfect Day licensing dairy proteins to food manufacturers and Onego Bio pursuing GRAS status to supply bioalbumen egg proteins to ingredient buyers, enabling asset-light scaling through technology licensing.

What valuation ranges and investment terms are characterizing the current market?

Most private funding rounds in 2024-Q1 2025 did not disclose pre-money valuations, but industry data suggests average Series B valuations in food-tech have trended downward to the $50-100 million range due to increased investor caution and focus on profitability metrics.

Down rounds and flat valuations became more common as companies prioritized runway extension over valuation growth, with several companies accepting lower per-share prices in exchange for stronger balance sheets and longer development timelines.

Liquidation preferences have become more investor-friendly, with many rounds including 1.5x to 2x liquidation preferences and anti-dilution provisions that protect investors in subsequent down rounds, reflecting the more challenging fundraising environment.

Strategic investors often secured board seats or observer rights in larger rounds, providing industry expertise and potential acquisition options while giving corporates insight into emerging technologies before competitors.

Revenue-based financing and convertible instruments gained popularity for later-stage companies with established sales, offering alternatives to traditional equity rounds while providing more favorable terms for companies with proven commercial traction.

How does 2024 funding compare to previous years and what's the 2025 outlook?

Total alternative protein funding declined 29% from $1.5 billion in 2023 to $1.1 billion in 2024, reflecting broader venture capital market contractions and increased investor selectivity following the sector's rapid growth in 2021-2022.

Q1 2025 showed $235 million in new investments, representing a 28% decline compared to Q1 2024 but a 102% increase from Q4 2024, suggesting potential stabilization after the 2024 correction with investors returning to selective deal-making.

The 2025 annualized run rate projects approximately $940 million in total funding assuming similar quarterly pacing, indicating the sector may have found a sustainable funding level between the 2023 peak and 2024 trough.

Deal count decreased more than total funding amounts, with average round sizes increasing as investors concentrated capital in proven companies with clear paths to profitability rather than spreading investments across numerous early-stage ventures.

Wondering who's shaping this fast-moving industry? Our slides map out the top players and challengers in seconds.

If you need to-the-point data on this market, you can download our latest market pitch deck here

What key trends are investors betting on for 2026 in the alternative protein market?

Cost reduction technologies top investor priorities for 2026, with capital allocation targeting bioprocess intensification including continuous fermentation systems, photomolecular reactors, and novel bioreactor designs that can achieve price parity with conventional proteins.

Sustainability metrics are increasingly driving investment decisions, with capital allocation linked to quantifiable GHG emissions reductions under emerging climate-bond criteria, requiring companies to demonstrate environmental impact alongside financial returns.

Platform technologies that can produce multiple protein types are attracting increased interest, as investors prefer companies that can address dairy, egg, and meat applications using the same core fermentation or cellular agriculture platform rather than single-product focused ventures.

Regulatory arbitrage opportunities are emerging as investors target companies with clear paths through specific regional approval processes, particularly EU Novel Food regulations and US GRAS status requirements where regulatory precedents are established.

Supply chain integration deals are expected to accelerate, with food giants acquiring or forming joint ventures with alternative protein companies to secure ingredient supplies and capture margin throughout the value chain rather than relying on third-party suppliers.

Are there signs of consolidation or strategic alliances forming in the alternative protein space?

Early consolidation signals are emerging through strategic partnerships like Cargill's pilot program with Perfect Day and Danone's exploration of fermentation startup acquisitions, indicating larger CPGs are moving from minority investments to potential majority control positions.

Formal industry alliances are developing, including the European Culinary Innovation Hub and USDA bio-economy consortia, which facilitate knowledge sharing, regulatory navigation, and collective scale-up efforts among member companies and research institutions.

Vertical integration is accelerating as ingredient suppliers acquire downstream capabilities and branded companies develop in-house production, reducing dependence on contract manufacturers and capturing more value chain margin.

Cross-border partnerships are increasing, particularly between US technology companies and European manufacturers who offer regulatory advantages and established distribution networks in markets where novel food approvals are more advanced.

Planning your next move in this new space? Start with a clean visual breakdown of market size, models, and momentum.

Which specific investment opportunities should entrepreneurs and investors prioritize?

Precision fermentation companies with GRAS-approved ingredients and established customer relationships represent the lowest-risk investment opportunities, particularly those targeting high-value applications like infant nutrition, sports nutrition, and functional foods where price premiums are sustainable.

B2B ingredient suppliers focused on improving manufacturing processes for existing alternative protein companies offer compelling opportunities, including novel separation technologies, flavor enhancement systems, and cost-reduction equipment that can serve multiple customers.

Companies developing platform technologies that can address multiple protein categories using the same core infrastructure attract premium valuations, as investors prefer businesses that can achieve economies of scale across dairy, egg, and meat applications.

Strategic positioning near major food manufacturing hubs in North America and Europe provides advantages for fundraising and partnership development, with proximity to potential customers and regulatory expertise significantly impacting commercial success rates.

Entrepreneurs should focus on technologies with clear paths to cost parity within 3-5 years rather than pursuing breakthrough innovations requiring 10+ year development timelines, as current investor sentiment favors near-term commercial viability over long-term potential.

Conclusion

Sources

1. Good Food Institute Investment Report
2. Vegconomist Q1 2025 Investment Analysis
3. Green Queen 2024 Funding Rounds Report
4. GFI Europe Investment Analysis
5. Food & Beverage European Investment Report
6. Food Business News Investment Analysis
7. Better Bioeconomy Q1 2025 Report
8. ProVeg Investment Hotspots Analysis